Cobimetinib: First Global Approval

Drugs

Volumn 75, Issue 15, 2015, Pages 1823-1830

  Garnock Jones, Karly P ^a  

^a Springer Mairangi Bay ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; COBIMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; GDC-0973; MITOGEN ACTIVATED PROTEIN KINASE; PIPERIDINE DERIVATIVE;

ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CHORIORETINOPATHY; DIARRHEA; DRUG APPROVAL; DRUG INDICATION; DRUG METABOLISM; FATIGUE; GENE MUTATION; HUMAN; MELANOMA; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RASH; RETINA DETACHMENT; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZETIDINES; DRUG APPROVAL; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDINES;

EID: 84945181972     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0477-8     Document Type: Article

References (28)

1. Sullivan R, LoRusso P, Boerner S, et al. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015:177-86. doi: 10.14694/EdBook-AM.2015.35.177.
2. Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27.
3. Rahman A. Vemurafenib and cobimetinib in BRAF-mutated melanoma. Lancet Oncol. 2014;15(12):e535.
4. Exelixis. Exelixis (EXEL) announces first regulatory approval of cobimetinib in Switzerland [media release]. 27 Aug 2015. http://www.biospace.com/.
5. ® (cobimetinib tablets): Swiss prescribing information. 2015. https://compendium.ch. Accessed 4 Sep 2015.
6. European Medicines Agency. CHMP summary of opinion (initial authorisation) for Cotellic (cobimetinib). 2015. http://www.ema.europa.eu. Accessed 28 Sep 2015.
7. Exelixis. Exelixis signs co-development agreement with Genentech for small molecule oncology compound [media release]. 3 Jan 2007. http://www.exelixis.com.
8. Exelixis. Option to develop Exelixis compound exercised by Genentech [media release]. 17 Mar 2008. http://www.exelixis.com.
9. Exelixis. Exelixis announces positive top-line results for phase 3 pivotal trial of cobimetinib in combination with vemurafenib in patients with BRAF V600 mutation-positive advanced melanoma [media release]. 14 Jul 2014. http://www.exelixis.com.
10. Exelixis. Exelixis announces first quarter 2007 financial results and business update [media release]. 3 May 2007. http://www.exelixis.com.
11. Rice KD, Aay N, Anand NK, et al. Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973). ACS Med Chem Lett. 2012;3(5):416-21.
12. Baudy AR, Dogan T, Flores-Mercado JE, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012;2(1):22.
13. Yan Y, McArthur G, Gajewski T, et al. Vemurafenib and cobimetinib potently inhibit PS6 signaling in BRAFV600 mutation-positive locally advanced or metastatic melanoma from BRIM7 study [abstract no. 1093PD]. Ann Oncol. 2014;25(Supplement 4):iv378.
14. Merchant M, Chan J, Orr C, et al. Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models [abstract no. 387]. Eur J Cancer. 2014;50(Supplement 6):124.
15. Aslan O, Farrelly AM, Stordal B, et al. Anti-tumour efficacy of the PI3 K inhibitor GDC0941, the dual PI3K/mTOR inhibitor GDC0980 and the MEK inhibitor GDC0973 as single agents and in combination in endometrial carcinomas [abstract no. 3079]. Eur J Cancer. 2013;49(Supplement 2):S736.
16. 3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumour growth inhibition in vivo [abstract no. 132]. JCC Suppl. 2010;8(7):48.
17. Musib L, Eppler S, Choo E, et al. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study [abstract no. 1304]. Cancer Res. 2011;71(8 Supplement).
18. Musib L, Choo E, Deng Y, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013;10(11):4046-54.
19. Wong H, Vernillet L, Peterson A, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012;18(11):3090-9.
20. Choo E, Takahashi R, Rooney I, et al. Assessing human absorption, metabolism, routes of excretion and the contribution of intestinal metabolism to the oral clearance of cobimetinib, a MEK inhibitor [abstract no. B160]. Mol Cancer Ther. 2013;12(11 Suppl. 1).
21. Han K, Jin J, Marchand M, et al. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors [abstract no. 2573]. J Clin Oncol. 2015;33(Supplement).
22. Choo EF, Ly J, Chan J, et al. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm. 2014;11(11):4199-207.
23. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-76.
24. Paolo Antonio A, Luis De La C-M, Daniil S, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from CoBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma [abstract no. 9006]. J Clin Oncol. 2015;33(15 Supplement).
25. Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954-65.
26. Pavlick AC, Ribas A, Gonzalez R, et al. Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma [abstract no. 9020]. J Clin Oncol. 2015;33(15).
27. Bendell JC, LoRusso P, Cho DC, et al. Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors [abstract no. CT328]. Cancer Res. 2014;74(19 Suppl. 1).
28. Russo PL, Shapiro G, Pandya SS, et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3 K inhibitor GDC-0941, in patients with advanced solid tumors [abstract no. 2566]. J Clin Oncol. 2012;30(15 Suppl. 1).